ACTEMRA/RoACTEMRA

Biologic monotherapy is sometimes necessary when treating patients with RA.1 In the subpopulation of patients not taking, or unable or unwilling to take, MTX, but in whom treatment is required, TNFi agents might not be the first choice of monotherapy given the evidence they are less effective as monotherapy than as combination therapy with MTX.1 Monotherapy with ACTEMRA/RoACTEMRA was superior to monotherapy with adalimumab in reducing signs and symptoms of RA in MTX-intolerant patients or patients for whom MTX treatment was considered inappropriate, as demonstrated in ADACTA, the first head-to-head superiority trial in RA biologic monotherapy.2 To explore the results of the first head-to-head superiority trial in RA biologic monotherapy click here.

ACTEMRA®/RoACTEMRA® (tocilizumab) is a first-in-class agent with a unique mechanism of action that targets the interleukin-6 receptor (IL-6R).The product is known as RoACTEMRA in the EU and Mexico and as ACTEMRA in the US and other countries.

RoACTEMRA, in combination with MTX, is indicated for the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.3 In these patients, RoACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

RoACTEMRA is indicated for the treatment of active sJIA in patients 2 years of age and older, who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. RoACTEMRA can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.3

RoACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor-positive or -negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.3

This website is intended as an extensive resource for healthcare professionals outside the US with an interest in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) and their treatment with ACTEMRA®/RoACTEMRA®. The information on this website is not country specific and may contain information that is outside the approved indication in your country. All information on this website is based on the European Summary of Product Characteristics (SmPC).

This site contains a wealth of resources including the mechanism of action, safety and efficacy information from key clinical trials, including the use of ACTEMRA/RoACTEMRA in monotherapy, and dosage and administration details. There is also a useful resource section containing a range of downloadable materials on RA, JIA and ACTEMRA/RoACTEMRA.

RoACTEMRA SmPC July 2013

Reference(s):

  1. Emery P, et al. Ann Rheum Dis  2013; 72: 1897–1904

  2. Gabay C, et al. Lancet 2013; 381:1541–1550

  3. RoACTEMRA® (tocilizumab) Summary of Product Characteristics. Roche Registration Limited. July 2013.

Country Websites

ACTEMRA in Monotherapy

ACTEMRA/RoACTEMRA shows superior disease control to adalimumab in biologic monotherapy in MTX-intolerant patients or patients for whom MTX treatment was considered inappropriate2

Learn more about ADACTA, the first head-to-head superiority trial in RA biologic monotherapy, and explore the ADACTA findings further in this section.

More

 

ACTEMRA/RoACTEMRA: A wealth of data in Monotherapy

This section contains information on the efficacy and safety profile of ACTEMRA/RoACTEMRA in biologic monotherapy, in patients who are methotrexate-naïve/free, and those who have an inadequate response to methotrexate (MTX-IR) or disease-modifying anti-rheumatic drugs including TNF inhibitors (DMARD-IR).

More